Back to Search
Start Over
Bayer Initiates Phase II Study Of Soluble Guanylate Cyclase Activator In Patients With Chronic Kidney Disease
- Source :
- Plus Company Updates. August 24, 2024
- Publication Year :
- 2024
-
Abstract
- BERLIN: Bayer announced the start of the ALPINE-1 study, a Phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase activator, in patients with chronic kidney disease. The results [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.807137645